Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4

BACKGROUND: Recently, everolimus was shown to improve median progression-free survival (PFS) by 7.1 months in patients with advanced, progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) tract compared with placebo (HR, 0.48; 95% CI, 0.35–0.67;...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Onco Targets Ther
Main Authors: Buzzoni, Roberto, Carnaghi, Carlo, Strosberg, Jonathan, Fazio, Nicola, Singh, Simron, Herbst, Fabian, Ridolfi, Antonia, Pavel, Marianne E, Wolin, Edward M, Valle, Juan W, Oh, Do-Youn, Yao, James C, Pommier, Rodney
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2017
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5652899/
https://ncbi.nlm.nih.gov/pubmed/29081664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S142087
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki